Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Wednesday, April 13, 2011

UK phase 1 - ADZ5363 - New cancer drug to be tested by patients - Business News - Healthcare Digital



"Medication that prevents the enzyme, Protein Kinase B (PKB), has the potential to treat breast cancer, prostate cancer, ovarian cancer, pancreatic cancer and gastric cancers.

The Royal Marsden NHS Foundation Trust and the Christie Hospital NHS Trust in the UK are going to be involved in testing the drug, along with a hospital in the Netherlands.

Scientists and doctors are looking for patients with advanced solid tumours to test the drug, in order to determine the safety, tolerability and initial anti-cancer activity of ADZ5363....."

Health briefs for April 13 - new clinical trial South Coast Gyn Oncology recruting: Trinova-1



Clinical studies

OVARIAN CANCER: South Coast Gynecologic Oncology is actively enrolling women with recurrent ovarian cancer for participation in a clinical research study called Trinova-1. The study is open to women 18 years or older who have been diagnosed with recurrent ovarian cancer, have undergone surgery to remove at least one ovary, and have been previously treated with chemotherapy. For details, call Judith Addison, RN, of South Coast Gynecologic Oncology at 858-455-5524 or visit www.TRINOVA-1.com.

Money, Marketing, and Ethics: Can They Work Together? (breast cancer)



When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death - National Cancer Institute (discusses various tumor types....



Note: this NCI article does not include ovarian cancer but does include platinum/taxane combination therapies (Carboplatin, Taxol); the JAMA paper most likely included ovarian cancer, however, the full text of the article is pay-per-view ($$$)

"The results were published February 2, 2011, in JAMA.":


JAMA abstract:
Treatment-Related Mortality With Bevacizumab in Cancer Patients
A Meta-analysis

"The overall incidence of FAEs (fatal adverse events) with bevacizumab was 2.5%."

Complementary and alternative medicine dialogue lacking between patients, providers , April 13, 2011 News Release - National Institutes of Health (NIH)



The AARP/NCCAM survey was conducted by telephone interview in October 2010, with a random sample of 1,013 people aged 50 and older.
For a complete copy of the survey report, please visit http://nccam.nih.gov/news/camstats/2010/.

The cost of drugs: breaking the bank to stay alive - The Globe and Mail




Evidence Network of Canada



Welcome to The Health Evidence Network of Canada

EvidenceNetwork.ca is a non-partisan web-based project funded by the Canadian Institutes of Health Research and the Manitoba Health Research Council to make the latest evidence on controversial health policy issues available to the media. This site links journalists with health policy experts to provide access to credible, evidence-based information.

Canadian Women's Health Network - survey re: care in nursing homes/long-term care - cancer patients - take survey!



From the National Network on Environments and Women’s Health, York University
We are a group of researchers with the national working group, Women and Health Protection, based at York University. We have a longstanding interest in the uses of prescription medications and in this project want to learn about the experiences of people who have family members* in long-term care facilities who may be taking prescription drugs. Family members often have the most direct knowledge about these issues and have much to contribute to a discussion about medication use. We hope to find out more about these experiences from responses to this survey, and plan to use this (anonymously-provided) information to develop a series of recommendations that may make things better for seniors in care.
If you are involved with the care of someone in a nursing home or long term care facility, we invite you to fill out the survey found at the following link:
http://www.surveymonkey.com/s/J93382Q
The survey will take about 15-20 minutes to complete. All information you provide will be anonymous; no one is required to provide a name. More information about our research is provided in the introduction to the survey The closing date for completing this survey is Monday, 21 March 2011.
We thank you in advance for helping us out. And please pass this invitation to others you know who may have a family member* in long term care so we can hear from as diverse a group as possible. We have also attached a pdf of the survey if individuals would prefer to fill it in manually and return to us by mail.
Anne Rochon Ford, Co-Director
National Network on Environments and Women’s Health

Canadian Women's Health Network - employment opportunity - executive director



The Canadian Women’s Health Network (CWHN) is looking for a new leader.
Canada’s leading independent voice for trusted women’s health information is seeking a new Executive Director. The organization, with its head office in Winnipeg, has strong networks and affiliations throughout the country. The CWHN focuses on providing high quality information about women’s health for researchers, health care providers, policy makers and Canadian women.
We strive to be an independent, critical voice for women’s health in Canada. Throughout our 14-year history, we have helped to lead and define the women’s health agenda in this country. We have taken courageous positions, built strong communities, and spoken out on behalf of women and girls.
The CWHN is seeking an experienced, enthusiastic and determined champion for women’s health. We are looking for an exceptional woman to help us take our next steps into the future, a thoughtful leader with passion and a commitment to social change.
For the complete job posting, click the link below. Deadline is May 18, 2011.

abstracts/index: Gynecologic Oncology, Volume 121, Issue 1, Pages 1-244 (April 2011)



Note: this journal is pay-per-view ($$$)

Establishing specialty jurisdictions in medicine: the case of American obstetrics and gynaecology 2011 - Sociology of Health & Illness



Abstract
The profession of medicine has evolved into an extremely specialised occupation.

Yet, recent research has neglected the intra-occupational processes influencing medical specialisation.

This article aims to correct this oversight.

It develops an historical account of intra-occupational factors influencing the decision to establish gynaecologic oncology as American ob/gyn’s surgical subspecialty in 1972. Working within the framework initially developed by Everett C. Hughes and his students, the article examines this development as the outcome of a three-party relationship among gynaecologic oncologists, American ob/gyns, and gynaecologic pelvic surgeons.

Aggressive movement by the gynaecologic pelvic surgeons challenging the established élite’s identity definition for the ob/gyn specialty helped spur official recognition of gynaecologic oncology, a less threatening subspecialty. The article draws theoretical implications from the case regarding the role of a threatening other in influencing the specialisation process.